非布索坦可以医保吗？

Can I get medical insurance? This is an issue that most patients are concerned about. The State Food and Drug Administration of China issued a new drug certificate for Febuxostat tablets to Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd. on June 26, 2013. The approved tablets are 40mg×16 tablets/box and 80mg×6 tablets/box. So, is Febuxostat covered by medical insurance? Let's take a look.

On June 26, 2013, the imported original drug Febuxostat was officially launched in China. Febuxostat has been included in the national medical insurance, with the number 911. The drug name is febuxostat. The dosage form is oral sustained-release dosage form. The drug category is musculo-skeletal system drugs > anti-gout drugs (XM> Febuxostat has become a new first-line product for the treatment of gout due to its quick effect and few side effects. Since febuxostat is expensive in China, many patients can only stay away. So, what is the price of generic febuxostat? According to Medical Travel, Febuxostat produced by Zydus Pharmaceuticals in India has the same efficacy as the original drug, but the price is indeed much lower. The specification is 80mg*30 tablets/box. Its price is about 200$. Due to exchange rate fluctuations, the price cannot be accurate. Please contact Medical Companion Travel for specific prices.  

On the clinical side, if a patient is found to have abnormal liver function (ALT more than 3 times the upper limit of the reference range), the medication should be discontinued and investigated to determine the possible cause. Febuxostat should not be reintroduced in these patients who have abnormal liver function tests and no other reasonable explanation. If the patient's serum ALT exceeds more than 3 times the reference range, and the serum total bilirubin exceeds more than 2 times the reference range, and other causes are excluded, the patient is at risk of severe drug-induced liver damage, and these patients should not restart febuxostat.  

For patients with small increases in serum ALT or bilirubin and other reasonable explanations, febuxostat should be treated with caution. Secondary Hyperuricemia There are no studies on the use of this product in patients with secondary hyperuricemia (including organ transplant recipients). Therefore, it is not recommended to use this product in patients with large increases in urate (such as malignant diseases, Lesch-Nyhan syndrome).  

We can know from the above understanding. As early as June 26, 2013, the imported original research drug Febuxostat was officially launched in China. It has been included in the national medical insurance, numbered 911, and the drug name is febuxostat.